Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 4;12:746922. doi: 10.3389/fonc.2022.746922

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yuasa, Urasaki and Oki

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Schematic of standard of care in 2022 for medical treatment of metastatic urological cancers, including renal cell cancer (mRCC, A), urothelial cancer (mUC, B), and hormone naïve prostate cancer (mHNPC, C). Abbreviations: CR: complete response; PR: partial response, SD: stable disease; mBRCA(-): BRCA1/2 mutation negative; mBRCA(+): BRCA1/2 mutation positive; Caba: cabazitaxel; Abi: abiraterone acetate; Enz: enzalutamide; MSI-high: microsatellite instability-high. *When docetaxel is administered as the first-line therapy for metastatic hormone-sensitive prostate cancer (HSPC), abiraterone acetate, enzalutamide, cabazitaxel, Ra-223, pembrolizumab (MSI-high), and olaparib (mBRCA[+]) are the candidates for metastatic castration-resistant prostate cancer (CRPC).